# Common Safety Follow-up Trial of Tecemotide (L-BLP25)

> **NCT01423760** · NA · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 27 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Tecemotide
- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT01423760
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2015-07
- **Final completion:** 2015-08
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.
- **Last updated:** 2016-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423760, "Common Safety Follow-up Trial of Tecemotide (L-BLP25)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01423760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*